LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA

I. S. Romanov; Романов И. С.; A. M. Mudunov; Мудунов А. М.; P. A. Isaev; Исаев П. А.; Yu. M. Bychkov; Бычков Ю. М.; M. B. Dolgushin; Долгушин М. Б.; A. A. Odzharova; Оджарова А. А.; L. F. Romanova; Романова Л. Ф.

doi:10.17650/2222-1468-2017-7-2-45-52

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA

Authors: Romanov I.S.¹, Mudunov A.M.¹, Isaev P.A.², Bychkov Y.M.³, Dolgushin M.B.¹, Odzharova A.A.¹, Romanova L.F.¹
Affiliations:
1. N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
2. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
3. Russian Scientific Center of Radiology
Issue: Vol 7, No 2 (2017)
Pages: 45-52
Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
Published: 27.06.2017
URL: https://ogsh.abvpress.ru/jour/article/view/264
DOI: https://doi.org/10.17650/2222-1468-2017-7-2-45-52
ID: 264

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Well-differentiated thyroid carcinoma (WDTC) comprises > 90 % of all cases of thyroid cancer. In 10–15 % of patients, distant metastases are detected which significantly worsen the prognosis. Radioactive iodine therapy remains the main type of treatment of this patient group, but for patients with so-called radioactive iodine-refractory WDTC the prognosis is very poor. After successful phase III studies, several drugs from the group of multikinase inhibitors are being used in clinical practice for treatment of radioactive iodine-refractory WDTC, for example lenvatinib. In this article, we present a group of patients with radioactive iodine-refractory WDTC who received lenvatinib therapy.